Central Pharmaceutical Joint Stock Company No3 (DP3) Q4 2024 earnings summary

Executive summary

• Net revenue for 2024 reached VND 417.5 billion, up 1.9% year-over-year; net profit after tax was VND 121.2 billion, down 3.3% from 2023.

• Gross margin improved to 33.9% from 31.3% year-over-year, reflecting better cost control.

• Cash and cash equivalents at year-end increased to VND 13.7 billion from VND 5.4 billion at the start of the year.

• Dividend payout for the year was VND 64.5 billion.

Financial highlights

• Net revenue: VND 417.5 billion (up from VND 409.7 billion year-over-year).

• Net profit after tax: VND 121.2 billion (down from VND 125.3 billion year-over-year).

• Gross profit: VND 141.4 billion (up from VND 128.2 billion year-over-year).

• Operating cash flow: VND 100.8 billion (down from VND 148.8 billion year-over-year).

• Basic EPS: VND 5,636 (down from VND 5,826 year-over-year).

Outlook and guidance

• No explicit forward guidance provided, but stable revenue and profit levels suggest continued focus on core pharmaceutical operations.